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Background: Chronic obstructive pulmonary disease (COPD) is hallmarked by inflammatory processes and a
progressive decline of lung function. YKL-40 is a potential biomarker of inflammation and mortality in patients suffering
from inflammatory lung disease, but its prognostic value in patients with COPD remains unknown. We investigated
whether high plasma YKL-40 was associated with increased mortality in patients with moderate to very severe COPD.
Methods: Four hundred and ninety-three patients with moderate to very severe COPD were followed prospectively
for up to 10 years. Patients were divided into two groups according to plasma YKL-40: concentration higher than the
75th percentile for age-matched healthy subjects (i.e. high levels) and normal levels. Outcome was overall survival (OS)
and was evaluated in uni- and multivariate proportional hazards Cox regression analyses and adjusted for factors
affecting mortality.
Results: Median plasma YKL-40 was increased in patients with COPD (81 ng/ml, p < 0.001) compared to healthy
subjects (40 ng/ml). Patients with high plasma YKL-40 had a hazard ratio (HR) of 1.42 (95% CI: 1.15–1.75, p = 0.001)
for all-cause mortality. Multivariate analysis showed that YKL-40 (HR 1.38; 95% CI: 1.11–1.72, p = 0.004), age (HR 1.05;
95% CI: 1.03–1.06, p < 0.0001), Severe COPD (HR 1.35; 95 CI: 1.03-1.76, p = 0.03) very severe COPD (HR 2.19; 95% CI:
1.60 - 2.99 < 0.0001), neutrophil granulocyte count (HR 1.05; 95% CI: 1.01-1.08, p = 0.01), and a smoking history
of > 40 years (HR 1.38; 95% CI: 1.11-1.71, p = 0.003) were independent prognostic markers of OS.
Conclusion: High plasmaYKL-40 is associated with increased mortality in patients with moderate to very severe
COPD, suggesting a role for YKL-40 as a potential biomarker of mortality in this patient group.
Trial registration: ClinicalTrials.gov: NCT00132860.
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Airflow limitation is a central feature of chronic ob-
structive pulmonary disease (COPD). The airflow limita-
tion is irreversible, and it is recognized that localized
tissue destruction in response to inflammatory processes
in lung tissue due to prolonged exposure to noxious
gases like tobacco smoke is associated with the develop-
ment of COPD (http://www.goldcopd.org – accessed 1
February, 2013). The disease is usually progressive, and
it is one of the leading causes of death in the Western
world [1,2]. In addition to localized inflammation in lung* Correspondence: Aesklepios@gmail.com
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distribution, and reproduction in any mediumtissue, systemic low grade inflammation is recognized as
part of the disease spectrum in COPD [3,4]. Basal levels
of systemic inflammation could reflect disease activity
and thus be a valuable tool in determining disease activ-
ity in patients with COPD.
The plasma concentration of YKL-40 (also called
chitinase3-like-1 (CHI3L1)) has attracted attention as a
biomarker of disease activity in a wide array of diseases
hallmarked by chronic low grade inflammation, tissue re-
modeling, and fibrosis, e.g. cardiovascular diseases [5-7],
asthma [8], diabetes mellitus type 1 [9] and 2 [10,11],
rheumatoid arthritis [12], liver fibrosis [13-15], and cancer
[16]. Furthermore, YKL-40 levels have been shown to be a
strong predictor of overall mortality in patients admitted
to hospital irrespective of diagnosis [17].tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Inclusion and exclusion criteria for the study
Inclusion criteria Exclusion criteria
• Patients above 50 years of age,
with a prior admission for
exacerbation of COPD within the
last two years.
• Patients with end-stage COPD,
who are not expected to survive
for 3 years (typically bedridden
patients being dyspnoeic at rest).
• Current or ex-smoker • Patients with known other
respiratory tract infection, e.g.
tuberculosis or aspergillosis, in
whom the intervention is known
to be inefficient.
• Postbronchodilator FEV1 < 60%
in stable condition (> 4 weeks after
hospitalization)
• Patients with pulmonary
malignancy
• < 300 ml bronchodilator
reversibility in FEV1
• Patients with other pulmonary
diseases than COPD
• Patients with immunodeficiency.
However, COPD patients treated
with steroids can be included
• Patients with known hereditary
disposition to lung infections such
as alfa-1-antitrypsin deficiency,
cystic fibrosis or primary ciliary
dyskinesia.
• Patients receiving long-term
antibiotic treatment
• (e.g. recurrent cystitis)
• Patients with known allergy or
intolerance to azithromycin
• Pregnant or breastfeeding
women
• Manifest heart, liver or renal
insufficiency
• Patients that, for reasons not
stated above, are unlikely to be
able to participate in a study
period of 3 years.
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40 is mainly secreted by cancer cells, macrophages, and
neutrophils [16,19]. Studies suggest that YKL-40 plays a
role in cell proliferation and differentiation [20], inflam-
mation [21,22], extracellular tissue remodeling [21], and
protection against apoptosis [23]. YKL-40 also induces
cancer angiogenesis both independently and through
stimulation of vascular endothelial growth factor [24]. In
Streptococcus pneumoniae infected CHI3L1 null mice,
YKL-40 is a regulator of antibacterial responses that
augment antimicrobial resistance by contributing to bac-
terial killing and controlling bacterial dissemination [25].
Recently, it has also become increasingly evident that
YKL-40 plays a role in inflammatory lung diseases. In-
creased concentrations of YKL-40 in plasma and broncho-
alveolar lavage fluid are found in patients with asthma [8],
COPD [26], and idiopathic pulmonary fibrosis (IPF) [27].
Interestingly, high YKL-40 levels predicted short survival
in 85 patients with IPF [27]. When exposed to YKL-40,
macrophages from COPD patients produce elevated levels
of the pro-inflammatory biomarkers IL-8, MCP-1, MIP-
1α, and MMP-9 [26], and YKL-40 is secreted from alveo-
lar macrophages when these are stimulated by TNF-α.
Serum YKL-40 is positively correlated to low-attenuation
area percentage a marker of the extent of lung emphy-
sema, and negatively correlated to forced expiratory
volume in 1 second (FEV1)% predicted, a marker of dis-
ease severity, in patients with COPD [28] and patients
with asthma [8]. A single nucleotide polymorphism in the
promoter of the CHI3L1 gene (−131 C→G) of patients
with asthma was correlated with elevated serum YKL-40,
bronchial hyper reactivity, and pulmonary function [29].
Knockdown of the CHI3L1 gene in a human airway epi-
thelia cell line protected the cell line against hypoxic cell
damage [30], further substantiating the pro-inflammatory
role of YKL-40 in inflammatory pulmonary disease.
In this study we investigated whether plasmaYKL-40
levels above the age-corrected 75% percentile were asso-
ciated with long-term mortality in a group of patients
with moderate to very severe COPD. We also examined
whether there was a relationship between COPD severity
and plasmaYKL-40 as previously reported. The hypoth-
esis was that plasma concentrations of YKL-40 above
the 75% age-corrected percentile reflect increased basal
inflammation in patients with moderate to very severe
COPD which is implied by an increased mortality rate in
patients with COPD. We tested this hypothesis in 493
patients with COPD followed for 10 years.
Methods
Study population
In all, 575 patients with COPD were enrolled from May
2001 to April 2004 in a randomized clinical trial study-
ing the effect of azithromycin 500 mg, 3 days per monthfor 36 months. Primary outcome was change in post-
bronchodilator FEV1. Secondary outcomes included num-
ber of hospital admissions, number of days in hospital,
mortality, quality of life, use of medication, prevalence of
respiratory pathogens, and prevalence of macrolide resis-
tance. Inclusion and exclusion criteria are explained in
detail in Table 1, and the trial was registered at http://
clinicaltrials.gov/- identifier NCT00132860 (accessed 1
September 2012). Ethical permission for the study was
obtained from the Regional Scientific Ethical Committee
for Southern Denmark, approval number VF 19990031.
Written informed consent for participation in the study
was obtained from all participants before inclusion.
YKL-40 analysis and reference interval
Plasma samples for YKL-40 analysis were available
from 493 patients. Bloodsampling was done at baseline
a time where patients were in a stable phase of the dis-
ease i.e. no prior admissions within the last month and
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sampling. Blood for EDTA plasma was centrifuged within
1 hour after blood sampling and then stored at −80°C until
analysis. The plasma levels were analyzed in February
2011. YKL-40 concentrations in plasma has been shown
to be stable for up to 16 years when frozen at −80°C de-
grees [31]. The plasma concentration of YKL-40 was de-
termined in duplicate by a commercial enzyme-linked
immunosorbent assay (ELISA) (Quidel, Santa Clara,
CA, USA) according to the manufacturer’s instructions.
The detection limit was 10 ng/ml, and intra- and inter-
assay coefficients of variation (CVs) were < 5% and < 6%.
The reference interval for plasma YKL-40 was deter-
mined from a previous study in which 3130 healthy sub-
jects (1837 women, 1293 men) aged 21–84 years from the
Danish general population, the Copenhagen City Heart
Study were examined for YKL-40 concentrations [31].
They had no known disease at the time of blood sam-
pling in 1991–1994 and remained healthy and alive dur-
ing the 16-year follow-up period. From this study an age
dependent correlation was found between age and
plasma concentrations of YKL-40 and a formula has
been extrapolated from this study [31] which we applied
to our present study.
Statistics
For all participants, person-years of follow-up were com-
puted from their inclusion in the study (May 2001 to April
2004) until date of death, emigration, lost to follow-up, or 31
January 2011 (last day of follow-up), whichever came first.
Patients’ date of death was registered in the Danish Central
Registry. Follow-up at 10 years was 99.4% complete.
Primary endpoint was overall survival (OS). Analyses of
measurements for time to death were done using the Cox
proportional hazards model. Patients were divided into
two groups according to plasma YKL-40: concentrations
higher than the 75th percentile for age-matched healthy
subjects (high levels) and normal levels. This was per-
formed using an equation from a previous report of
plasma YKL-40 in 3130 healthy subjects in which the
75th percentile was used as a cut-off value to define a
high YKL-40 level [31]. Survival probabilities for OS
were estimated by the Kaplan-Meier method, and tests
for differences between strata were done using the log-
rank statistic.
Multivariate analysis included plasmaYKL-40 above 75%
of the age-adjusted level, COPD stage as defined by the
GOLD initiative i.e. Moderate COPD ( 79–50 FEV1%
predicted), severe COPD (30–50 FEV1% predicted) [32],
and very severe COPD (< 30 FEV1% predicted), Charlson
Comorbidity Index > 2, age (as a continuous variable),
treatment group (azithromycin vs. placebo), and gender
as possible confounders. In addition to these, potential
confounders were tested in univariate analysis andincluded in the final model if they were significant at a
level of 0.25 or below. The number of events (376 patients
died) was within the 10 events per variable suggested by
Peduzzi et al. [33].
Variables were tested for interaction by likelihood ratio
test statistics and no significant interactions were found.
Continual confounders were all tested for linearity. Pro-
portional hazards assumptions were tested individually for
each confounder. We used log-log plots and observed vs.
expected plots for categorical confounders and observed
vs. expected plots for continuous confounders. No viola-
tion was displayed on confounders. Further analysis was
performed using multivariate Cox proportional hazards
models. Results were presented as median with 95% confi-
dence interval (CI) or interquartile range or rates as ap-
propriate. All statistical analyses were carried out using
STATA 11.1 (Stata Corp LP, TX, USA).
Results
Study population characteristics
The study population consisted of 493 individuals (247
males and 246 females) characterized by fairly advanced
COPD, with a median FEV1% predicted of 38.5%. Of these,
129 (26%) had moderate COPD, 250 (51%) had severe, and
114 (23%) had very severe COPD. Median plasma YKL-40
was increased in patients with COPD (81 ng/ml, range
13–925 ng/ml) compared to healthy controls 40 ng/ml).
In all, 376 (76%) patients died during the 10-year follow-
up period.
Patients were divided into two groups defined by plasma
YKL-40: higher (n = 171) or below (n = 322) the age-
corrected 75% percentile of plasma YKL-40 in a large
group of healthy subjects. Table 2 gives clinical character-
istics of the patients. The groups displayed a homogenous
composition, but plasmaYKL-40 above the 75% age-
corrected percentile was associated with a higher Charlson
Score Index.
Plasma YKL-40 and FEV1
We also investigated whether there was an association
between plasma YKL-40 and lung function. The results
are displayed in the subsection “PlasmaYKL-40 and COPD
severity” (Figure 1).
Univariate survival analysis
Univariate analysis showed that plasma YKL-40 dichoto-
mized to levels above the age-adjusted 75% percentile in
healthy subjects was associated with shorter OS (HR =
1.42, p = 0.001) (Table 3). In addition to plasma YKL-40
levels, age, neutrophil granulocyte count, severe/very
severe COPD, and a smoking history of more than 40
pack years were also associated with increased mortality
(Table 3).
Table 2 Baseline variables distributed according to plasma concentrations of YKL-40
< 75% percentile (n = 322) > 75% percentile (n = 171) p-value
Age at index date‡ 70 (65–75) 72 (66–76) 0.16
Charlson score‡* 1 (1–2) 1 (1–3) 0.02
Smoking (years)‡ 37 (26–50) 40 (28–55) 0.13
Neutrophils (x10^9/L)‡ 6.2 (4.7-8.0) 6.3 (4.9-8.9) 0.18
FVC (L)‡ 2.00 1.91 0.09
FEV1 (L)‡ 0.89 (0.69-1.15) 0.91 (0.69-1.13) 0.72
FEV1 predicted (%)‡ 37.69 (29.73-47.25) 40.68 (31.03-49.67) 0.23
BMI‡ 24.20 (21.04-27.83) 24.01 (20.08-27.24) 0.20
Present smokers§ (%) 120 (37) 76 (44) 0.12
Male gender†§ (%) 164 (51) 83 (49) 0.61
Randomization azithromycin§ (%) 164 (51) 84 (49) 0.70
*Significant difference using Kruskal-Wallis equality-of-populations rank test.
‡Values are median (interquartile range).
§Values are number (%).
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according to different categorical variables associated
with OS in the univariate analysis (2A: high YKL-40 vs.
normal; 2B: COPD severity; 2C: pack years above 40 vs.
lower levels). Patients with high plasma YKL-40 had a
50% cumulative survival of only 40 months in contrast
to patients with normal plasma YKL-40 who had a 50%
cumulative survival of 62 months. We also investigated
whether high levels of plasma YKL-40 retained a dis-
criminative effect when patients were stratified into dif-
ferent levels of COPD severity. Even though this was not
the case for patients with moderate COPD, such an0
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Figure 1 Plasma YKL-40 and COPD severity. Boxplots of plasma concen
Moderate COPD (79–50 FEV1 % predicted), severe COPD (30–50 FEV1 % pr
score is the line in the middle of the box, and the 25th and 75th percentile
95th percentiles. Outliers are given as dots. No significant differences wereassociation was displayed for patients with severe and
very severe COPD (Figure 3A-C).
Multivariate survival analysis
To determine the independent effect of plasma YKL-40
on OS, we included age and neutrophil granulocytes as
continuous variables and Charlson Comorbidity Index,
COPD severity, and pack years as categorical variables.
Patients with COPD and high age-adjusted plasma YKL-40
had shorter OS (HR = 1.39, 95% CI: 1.12–1.73, p = 0.004).
Age (HR = 1.04, p < 0.0001), neutrophil granulocyte count
(HR = 1.04, p = 0.03), severe COPD (HR = 1.33, p = 0.04),P=0.11
re COPD Very Severe COPD
(N = 250) (N = 114)
trations of YKL-40 in patients with COPD according to disease severity.
edicted) and very severe COPD (< 30 FEV1 % predicted). The median
s are the lower and upper part of the box. The whiskers are the 5th and
found (Kruskal-Wallis test).
Table 3 Univariate analysis of potential predictors of mortality
Hazard rate 95% Confidence interval p-value
High vs. normal plasma YKL-40** 1.42 1.15 – 1.75 0.001
Age* 1.04 1.03 – 1.06 <0.001
Neutrophils† 1.05 1.01 – 1.09 0.006
Charlson score index > 2 1.21 0.94 – 1.54 0.14
Moderate COPD‡ Ref. value Ref. value -
Severe COPD‡ 1.38 1.06 – 1.77 0.014
Very severe COPD‡ 1.94 1.45 – 2.60 <0.001
Smoking at baseline 1.10 0.90 – 1.35 0.36
BMI < 20 1.17 0.91 – 1.50 0.21
Pack years > 40 1.29 1.05 – 1.58 0.014
*Estimated hazard ratio associated with an increment of one year.
**Patients were dichotomized according to the 75th percentile of plasma YKL-40 in age-matched healthy subjects (30).
†Estimated hazard ratio associated with an increment of 1 * 109 cells/L.
‡Moderate COPD (79–50 FEV1 % predicted), severe COPD (30–50 FEV1 % predicted) [32], and very severe COPD (< 30 FEV1 % predicted).
Holmgaard et al. BMC Pulmonary Medicine 2013, 13:77 Page 5 of 10
http://www.biomedcentral.com/1471-2466/13/77very severe COPD (HR = 2.22, p < 0.0001), and a smoking
history in excess of 40 pack years (HR = 1.36, p = 0.009)
were also independent parameters of short OS (Table 4).
Discussion
COPD is characterized by a localized and usually pro-
gressive destruction of lung tissue, and increasing aware-
ness has been given to the systemic effects of COPD. It
is believed that the ongoing inflammation in the lungs
“overspills” into the systemic circulation. Monitoring of
systemic inflammatory biomarkers may reflect disease
activity in patients with COPD, and would help to moni-
tor disease progression, treatment efficacy, and identifi-
cation of COPD phenotypes that would benefit from
disease modifying pharmacotherapy.
Several putative inflammatory biomarkers in plasma or
serum like C-reactive protein (CRP) [34,35], pulmonary
and activation-regulation chemokine (PARC/CCL-18)
[36], and fibrinogen [37] have been tested for their abil-
ity to predict all-cause and COPD-related mortality in
patients with various stages of COPD. Despite showing
promise as prognostic biomarkers, serum CRP and fi-
brinogen are not modified by potent inflammation
modifying medications [38]. A general consensus on the
ability of serum CRP to predict mortality was challenged
in a study which was unable to demonstrate the same
predictive value of serum CRP on mortality in patients
with moderate to very advanced COPD [39]. Further-
more, the repeatability of serum CRP in patients with
COPD and stable disease showed a high degree of vari-
ability, suggesting that the use of serum CRP as a bio-
marker of basal disease activity in patients with COPD is
unfeasible [40].
The reasons for these ambiguous results can be many,
but a recent study found that only a subset of patients
with COPD is characterized by persistent systemicinflammation and the authors propose that a clinical
phenotype with persistent inflammation is the reason for
this [41]. In this study patients with persistently elevated
levels of a select group of inflammatory biomarkers (IL-
6, CRP, fibrinogen and white blood cells) were associated
with an adverse outcome. These findings are very interest-
ing as a very recent study found that IL-6 levels increased
during a three year period whereas no change was appar-
ent in mean CRP levels. IL-6 levels correlated with six-
minute walk distance and mortality further corroborating
a role of IL-6 as a marker of persistent inflammation [42]
an interesting finding as a fairly recent study found that
IL-6, but not TNF-α, stimulates YKL-40 production.
These results suggest that IL-6 could be an upstream ac-
tivator of YKL-40 independent of TNF-α [43]. In the
present study of patients suffering from moderate to very
severe COPD, we found that a high plasma concentration
of YKL-40 was an independent predictor of shorter OS.
This is a novel observation in COPD patients. The study
benefited from a fairly large number of 493 well-
characterized patients, and within the study period of
10 years, follow-up was almost complete (99.4% complete).
In addition to this, the study population carried a very
high fatality rate, and more than 76% of the population
died during the study period.
Our primary outcome was all-cause mortality. We did
not have access to cause-specific mortality in this study.
It is well known that patients suffering from COPD are
subject to co-morbidities, e.g. lung cancer and cardiovascu-
lar disease, which are associated with elevated plasma con-
centrations of YKL-40 and increased mortality [5,6,16,44].
We cannot rule out that these causes of death were a con-
tributing factor to death in our cohort. However, the pa-
tients were excluded from inclusion into the study if they
suffered from pulmonary malignancies, other pulmonary
disease, or if they were suffering from advanced heart or
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Figure 2 Kaplan-Meier survival curves showing the association between plasma YKL-40 and 10-year OS. Patients were dichotomized
according to 75th percentile of plasma YKL-40 in age-matched healthy subjects (A), COPD severity (B), and 40 pack years (C). P-value refers to the log-rank
test for equality of strata. Moderate COPD (79–50 FEV1 % predicted), severe COPD (30–50 FEV1 % predicted) and very severe COPD (< 30 FEV1 % predicted).
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Figure 3 Kaplan-Meier survival curves showing the association between plasma YKL-40 and 10 year OS in patients with different
degree of disease severity. Patients were dichotomized according to the 75th percentile of plasma YKL-40 in age-matched healthy subjects. Patients
were divided into groups with moderate COPD (A), severe (B) and very severe COPD (C). P-value refers to the log-rank test for equality of strata.
Holmgaard et al. BMC Pulmonary Medicine 2013, 13:77 Page 7 of 10
http://www.biomedcentral.com/1471-2466/13/77
Table 4 Multivariate proportional hazards Cox regression of prognostic markers for mortality
Adjusted hazard ratio 95% Confidence interval p-value
High vs. normal plasma YKL-40** 1.38 1.11 - 1.72 0.004
Age* 1.05 1.03 - 1.06 <0.0001
Neutrophils† 1.05 1.01- 1.08 0.01
Moderate COPD‡ Ref. Value Ref. Value Ref. Value
Severe COPD‡ 1.35 1.03 - 1.76 0.03
Very severe COPD‡ 2.19 1.60 - 2.99 <0.0001
Pack years > 40 1.38 1.11- 1.71 0.003
*Estimated hazard ratio associated with an increment of one year.
**Patients were dichotomized according to the 75th percentile of plasma YKL-40 in age-matched healthy subjects (30).
†Estimated hazard ratio associated with an increment of 1 * 109 cells/L.
‡Moderate COPD (79–50 FEV1 % predicted), Severe COPD (30–50 FEV1 % predicted) [32].
and Very Severe COPD (< 30 FEV1 % predicted).
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death is underreported, and hence a more general inquiry
into causes of death would most likely underestimate
COPD as cause of death [45].
Our study suffered from lack of a healthy control group.
When we compared plasma YKL-40 of the patients with
age-adjusted plasma YKL-40 in a large group of 3130
healthy subjects from the general population [31], we
found that 35% of the patients with COPD had a plasma
YKL-40 level higher than the age-corrected 75% level in
healthy subjects. In the literature, the cut-off values for
high/normal plasma YKL-40 in patients with cancer are
often set at 90% or 95%. If these cut-offs were used, 17%
of the COPD patients had a plasma YKL-40 level higher
than the 90% upper normal level, and only 8% of the
COPD patients had a plasma YKL-40 level higher than
the 95% upper normal level. We initially decided to use
the age-corrected 75% percentile because we deemed it
reasonable that levels above this cut-off would indicate
low- grade increased inflammatory activity in COPD.
We thought it less likely that plasma YKL-40 would
elevate to levels comparable to those seen in metastatic
cancer.
Corticosteroids decrease plasma concentrations of YKL-
40 [46]. The use of corticosteroids was not registered in
our cohort of COPD patients at the time of enrollment.
But the blood samples used for determination of YKL-40
were drawn at time of inclusion in the study when the
patients were in a stable disease phase, and only a minor
group of patients were probably treated with oral
corticosteroids. Patients were excluded if they had been
treated with antibiotics up to 1 week before inclusion or if
they had a history of hospitalization within the last month.
This should minimize the risk of patients having active
infections or exacerbations present at the time of blood
sampling and would give a more accurate picture of
chronic inflammation in patients with COPD. We cannot
exclude that we underestimated the plasma levels of YKL-
40 in individual cases.The original trial investigated the effects of the antibiotic
azithromycin on a number of outcomes. Azithromycin is
a potent antibiotic but is also an anti-inflammatory drug.
This serves as a confounder when interpreting our results.
The distribution of patients receiving azithromycin was
comparable in patients with low or high plasma YKL-40
(Table 2). We were unable to demonstrate an effect of
azithromycin on OS in the univariate model or the final
multivariate model (results not shown). In addition to this,
the final multivariate model was tested in a model in
which we stratified into a group who had received treat-
ment vs. one that had not. These groups were then exam-
ined using a likelihood ratio test in which we compared
the two models against each other and no difference was
found (results not shown). Thus we do not believe this po-
tential confounder had any impact on the outcome of this
study.
An association between mortality and increased plasma
concentrations of YKL-40 does not prove causation. The
finding is interesting, however, as the same observation has
been made in patients suffering from IPF [27]. Increased
levels of several key inflammatory mediators are secreted
from macrophages in patients suffering from COPD, e.g.
IL-8, MCP-1, MIP-1α and MMP-9 when stimulated by
YKL-40 [26]. Intriguingly, stimulation of macrophages with
TNF-α results in increased secretion of YKL-40 [26]. This
potentially places YKL-40 centrally in the inflammatory
cascade between upstream signaling through TNF-α
and downstream signaling via IL-8, MCP-1, MIP-1α, and
MMP-9. These findings were recently contested however
and the role of YKL-40 in airway inflammation remains to
be elucidated (see above) [43].
The notion that high plasma YKL-40 is associated with
increased inflammatory response and a rapid decline of
lung function is supported by our findings of short OS.
Paraclinical findings in another study support this hypoth-
esis as high plasma YKL-40 was associated with high levels
of low-attenuation area percentage and a negative correl-
ation to FEV1% predicted [28].
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present study. As expected, patients with severe or very
severe COPD had shorter OS than did patients with
moderate COPD. We could not confirm that BMI and
Charlson Comorbidity Index were prognostic parame-
ters. The median BMI of 24 in our cohort was high,
and only 100 (20%) patients had BMI < 20. Twenty-six
percent of our patients had moderate COPD, and
Charlson Comorbidity Index may not accurately predict
mortality in patients suffering from advanced COPD. Such
patients are already at an increased risk of dying, and co-
morbidities may play a lesser role.
No association was found between FEV1% predicted
and plasma YKL-40 in our study. This is in contrast to
two earlier small studies of 45 and 50 patients with
COPD [26,28] reporting that plasma YKL-40 was related
to disease stage, i.e. related to the degree of airway ob-
struction measured by FEV1% predicted. The patients in
these studies suffered from a lesser degree of obstruction
and were younger than our patients, which may account
for some of the difference.
The parameter FEV1% predicted represents disease sta-
ging and does not provide information about how fast the
disease developed to the current level of airway obstruc-
tion, an observation that corresponds well with the recent
changes in the GOLD COPD disease staging guidelines
(http://www.goldcopd.org – accessed 17 April, 2013) in
which symptoms and exacerbations also have an influence
on disease staging. This may explain why we see this
discrepancy in our cohort. YKL-40 may more accurately
describe disease activity, whereas FEV1% represents the
current level of lung damage. This notion is supported by
our findings: a high plasma YKL-40 in patients with severe
and very severe COPD predicted a worse outcome inde-
pendent of the traditional disease staging levels
(Figure 3B-C). This could potentially signify that these
patients had a disease characterized by a higher degree of
inflammation and that plasma YKL-40 is able to assign pa-
tients with advanced disease to a high- and a low-risk
group independent of disease severity.
Identification of biomarkers that can predict progression
of COPD remains a high priority. Currently we only have
an indirect measure of COPD disease progression through
the use of spirometry. A biomarker level in a blood sample
able to assess the inflammatory activity in patients with
COPD would prove a valuable tool in monitoring disease
activity, treatment efficacy, and prognosis of patients. This
could help to identify patients characterized by high in-
flammatory activity who might benefit most from inflam-
matory modifying therapies.
Conclusion
In conclusion, our study supports the hypothesis that
plasma YKL-40 is elevated in many patients suffering fromadvanced COPD. Patients with the highest plasma YKL-40
had the shortest OS. The exact functions of YKL-40 in dis-
ease progression of COPD remain unknown. Prospective,
longitudinal studies of patients with COPD are needed
in which plasma YKL-40 is determined several times
during follow-up and related to clinical characteristics,
e.g. loss of FEV1. It would also be interesting to investi-
gate whether high plasma YKL-40 is associated with an
increased susceptibility to exacerbations of COPD. In-
creased inflammatory activity could potentially lead to
exaggerated responses to inflammatory insults to the
airways, and plasma YKL-40 may be a new prognostic
biomarker in patients with COPD.
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